Retention of heroin and morphine-6β-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1

Nature Neuroscience

Volumn 2, Issue 2, 1999, Pages 151-156

  Schuller, Alwin G P ^a   King, Michael A ^b   Zhang, Jiwen ^a   Bolan, Elizabeth ^b   Pan, Ying Xian ^b   Morgan, Daniel J ^a   Chang, Albert ^b   Czick, Maureen E ^a   Unterwald, Ellen M ^c,d,e   Pasternak, Gavril W ^b   Pintar, John E ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; MORPHINE; MORPHINE 6 GLUCURONIDE;

ANALGESIA; ANIMAL CELL; ARTICLE; DRUG RECEPTOR BINDING; EXON; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANALGESICS, OPIOID; ANIMALS; DRUG RESISTANCE; EXONS; HEROIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHINE DERIVATIVES; RECEPTORS, OPIOID, MU; TRANSCRIPTION, GENETIC;

EID: 0033366394     PISSN: 10976256     EISSN: None     Source Type: Journal    
DOI: 10.1038/5706     Document Type: Article

References (30)

1. Pasternak, G. W. Pharmacological mechanisms of opioid analgesics. Clin. Neuropharmacol. 16, 1-18 (1993).
2. Way, E. L., Young, J. & Kemp, J. Metabolism of heroin and its pharmacological implications. Bull. Narcotics 17, 25-33 (1965).
3. Way, E., Kemp, J., Young, J. & Grasetti, D. R. The pharmacologic effects of heroin in relationship to its rate of biotransformation. Pharmacol. Exp. Ther. 129, 144-154 (1960).
4. Oldendorf, W. H., Hyman, S., Braun, L. & Oldendorf, S. Z. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 178, 984-986 (1972).
5. Inturrisi, C. E. et al. The pharmacokinetics of heroin in patients with chronic pain. N. Engl. J. Med. 310, 1213-1217 (1984).
6. Inturrisi, C. E. et al. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci. 33 Suppl 1, 773-776 (1983).
7. Rossi, G., Pan, Y.-X., Cheng, J. & Pasternak, G. W. Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor. Life Sci. 54, PL375-379 (1994).
8. Rossi, G. C., Standifer, K. M. & Pasternak, G. W. Differential blockade of morphine and morphine-6 beta-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein alpha subunits in rats. Neurosci. Lett. 198, 99-102 (1995).
9. Rossi, G. C., Pan, Y.-X., Brown, G. P. & Pasternak, G. W. Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6 beta-glucuronide receptor. FEBS Lett. 369, 192-196 (1995).
10. Rossi, G. C., Brown, G. P., Leventhal, L., Yang, K. & Pasternak, G. W. Novel receptor mechanisms for heroin and morphine-6 beta-glucuronide analgesia. Neurosci. Lett. 216, 1-4 (1996).
11. Pasternak, G. W. & Standifer, K. M. Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Trends Pharmacol. Sci. 16, 344-350 (1995).
12. Pick, C. G., Nejat, R. J. & Pasternak, G. W. Independent expression of two pharmacologically distinct supraspinal mu analgesic systems in genetically different mouse strains. J. Pharmacol. Exp. Ther. 265, 166-171 (1993).
13. Moskowitz, A. S. & Goodman, R. R. Autoradiographic distribution of mu1 and mu2 opioid binding in the mouse central nervous system. Brain Res. 360, 117-129 (1985).
14. 3H-morphine-6beta-glucuronide binding in brain membranes and an MOR-1-transfected cell line. J. Pharmacol. Exp. Ther. 282, 1291-1297 (1997).
15. Standifer, K. M., Rossi, G. C. & Pasternak, G. W. Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G protein alpha subunits. Mol. Pharmacol. 50, 293-298 (1996).
16. Rossi, G. C. et al. Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6beta-glucuronide antinociception. J. Pharmacol. Exp. Ther. 281, 109-114 (1997).
17. Reisine, T. & Bell, G. I. Molecular biology of opioid receptors. Trends Neurosci. 16, 506-510 (1993).
18. Uhl, G. R., Childers, S. & Pasternak, G. An opiate-receptor gene family reunion. Trends Neurosci. 17, 89-93 (1994).
19. Zimprich, A., Simon, T. & Hollt, V. Cloning and expression of an isoform of the rat mu opioid receptor (rMOR1B) which differs in agonist induced desensitization from rMOR1. FEBS Lett. 359, 142-146 (1995).
20. Bare, L. A., Mansson, E. & Yang, D. Expression of two variants of the human mu opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett. 354, 213-216 (1994).
21. Matthes, H. W. et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383, 819-823 (1996).
22. Sora, I. et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl. Acad. Sci. USA 94, 1544-1549 (1997).
23. Tian, M. et al. Altered hematopoiesis, behavior, and sexual function in mu opioid receptor-deficient mice. J. Exp. Med. 185, 1517-1522 (1997).
24. Loh, H. H. et al. Mu opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Mol. Brain Res. 54, 321-326 (1998).
25. Chen, X. H. et al. An antisense oligodeoxynucleotide to mu-opioid receptors inhibits mu-opioid receptor agonist-induced analgesia in rats. Eur. J. Pharmacol. 275, 105-108 (1995).
26. Paul, D., Standifer, K. M., Inturrisi, C. E. & Pasternak, G. W. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J. Pharmacol. Exp. Ther. 251, 477-483 (1989).
27. Brown, G. P. et al. 3-Methoxynaltrexone, a selective heroin/morphine-6beta-glucuronide antagonist. FEBS Lett. 412, 35-38 (1997).
28. Huang, P. L., Dawson, T. M., Bredt, D. S., Snyder, S. H. & Fishman, M. C. Targeted disruption of the neuronal nitric oxide synthase gene. Cell 75, 1273-1286 (1993).
29. Brenman, J. E. et al. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell 84, 757-767 (1996).
30. Joyner, A. L. Gene Targeting: A Practical Approach (Oxford Univ. Press, Oxford, 1993).